11 – 20 of 32
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery-Results from RECUR Consortium
- Contribution to journal › Article
-
Mark
Novel Liquid Biomarkers and Innovative Imaging for Kidney Cancer Diagnosis : What Can Be Implemented in Our Practice Today? A Systematic Review of the Literature
- Contribution to journal › Scientific review
-
Mark
Updated European Association of Urology Guidelines on Renal Cell Carcinoma : Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma
- Contribution to journal › Article
-
Mark
The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma : Immune Checkpoint Inhibitor–based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care
- Contribution to journal › Debate/Note/Editorial
- 2020
-
Mark
Features of increased malignancy in eosinophilic clear cell renal cell carcinoma
- Contribution to journal › Article
- 2019
-
Mark
Increased use of cross-sectional imaging for follow-up does not improve post-recurrence survival of surgically treated initially localized R.C.C. : results from a European multicenter database (R.E.C.U.R.)
- Contribution to journal › Article
-
Mark
Updated European Association of Urology Guidelines on Renal Cell Carcinoma : Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma
- Contribution to journal › Article
- 2018
-
Mark
Metastases from Renal Cell Carcinoma. Recurrence Patterns, Detection and Management.
- Thesis › Doctoral thesis (compilation)
-
Mark
Updated European Association of Urology Guidelines : Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer
- Contribution to journal › Article
- 2017
-
Mark
Papillary renal cell carcinoma-derived chemerin, IL-8, and CXCL16 promote monocyte recruitment and differentiation into foam-cell macrophages
- Contribution to journal › Article
